- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Schizophreniform Disorder AND Psychotic Disorders AND Schizophrenia.
Displaying page 1 of 2.
EudraCT Number: 2015-001599-23 | Sponsor Protocol Number: SIMPET-1 | Start Date*: 2016-06-27 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Center Groningen | ||||||||||||||||||||||||||||
Full Title: In Vivo Imaging of Neuroinflammation in Simvastatin-Treated Schizophrenic Patients | ||||||||||||||||||||||||||||
Medical condition: Schizophrenia | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020185-19 | Sponsor Protocol Number: KP7242114 | Start Date*: 2011-05-30 | ||||||||||||||||
Sponsor Name:University Medical Center Utrecht | ||||||||||||||||||
Full Title: Optimization of Treatment and Management of Schizophrenia in Europe | ||||||||||||||||||
Medical condition: Schizophrenia ICD-10 code F20 or schizophreniform disorder ICD-10 code F23.1 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) DK (Prematurely Ended) AT (Completed) BE (Completed) IT (Completed) BG (Completed) RO (Suspended by CA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-011343-39 | Sponsor Protocol Number: RIS-SCH-4226 | Start Date*: 2009-06-15 | |||||||||||||||||||||||||||||||
Sponsor Name:Janssen-Cilag AB | |||||||||||||||||||||||||||||||||
Full Title: Patient and physician preferences and satisfaction with oral and long-acting injectable long-term antipsychotic treatment for psychotic disorders | |||||||||||||||||||||||||||||||||
Medical condition: Schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorder NOS or any other psychotic disorder patients demanding long term antipsychotic treatment | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004483-11 | Sponsor Protocol Number: 80-83600-98-40120 | Start Date*: 2016-07-08 | |||||||||||||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||||||||||||
Full Title: Raloxifene Augmentation in Patients with a Schizophrenia spectrum Disorder to reduce symptoms and improve cognition | |||||||||||||||||||||||
Medical condition: schizophrenia, schizoaffective, schizophreniform disorder or psychosis not otherwhise specified (DSM-IV 295.*) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) BE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000709-36 | Sponsor Protocol Number: 15/0947 | Start Date*: 2016-11-23 | ||||||||||||||||||||||||||
Sponsor Name:UCL | ||||||||||||||||||||||||||||
Full Title: Research into Antipsychotic Discontinuation and Reduction (RADAR): A Randomised Controlled Trial | ||||||||||||||||||||||||||||
Medical condition: Schizophrenia, delusional disorders, schizoaffective disorder, psychosis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000520-14 | Sponsor Protocol Number: NL46653 | Start Date*: 2014-07-31 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Prednisolone addition for atients with recent onset psychotic disorder: the role of immune-modulating strategies in the treatment of psychosis. | ||
Medical condition: Schizophrenia, schizophreniphorm disorder, schizoaffective disorder, psychosis NOS. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-001582-12 | Sponsor Protocol Number: 4 | Start Date*: 2023-03-01 |
Sponsor Name:Consorcio Centro de Investigacion Biomedica en Red (CIBER) | ||
Full Title: Open, multicenter, randomized clinical trial to evaluate the efficacy and safety of aripiprazole vs paliperidone / risperidone using multi-omics data in patients with a first psychotic episode. | ||
Medical condition: First episode SZ-spectrum individuals | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000053-27 | Sponsor Protocol Number: MELIA | Start Date*: 2020-07-09 |
Sponsor Name:UMC Utrecht | ||
Full Title: The MEtformin-LIfestyle in Antipsychotic users trial (MELIA): optimizing the use of metformin in the management of antipsychotic-induced weight gain. | ||
Medical condition: Antipsychotic-induced weight gain (AiWG) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004489-16 | Sponsor Protocol Number: V3_KET_NEG_SYMPT_SCZ | Start Date*: 2021-11-03 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Psychiatrie und Psychotherapie | ||
Full Title: Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study. | ||
Medical condition: Negative and depressive symptoms of schizophrenia according to DSM-5 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001337-40 | Sponsor Protocol Number: BXCL501-105 | Start Date*: 2021-10-05 | |||||||||||||||||||||
Sponsor Name:BioXcel Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | |||||||||||||||||||||||
Medical condition: Subject that meets DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder, or other specified/unspecified schizophrenia spectrum and/or other psychotic disorders OR Subjec... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Restarted) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000757-36 | Sponsor Protocol Number: ASA-CRP-01 | Start Date*: 2014-10-07 | ||||||||||||||||
Sponsor Name:Clinirx Tangent Research | ||||||||||||||||||
Full Title: A randomized trial administering aspirin vs. placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffective disorder with high CRP levels | ||||||||||||||||||
Medical condition: schizophrenia and schizoaffective disorder. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: RO (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001523-39 | Sponsor Protocol Number: D1050300 | Start Date*: 2013-11-08 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE 1 OPEN-LABEL, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LURASIDONE IN SUBJECTS 6 TO 17 YEARS OLD WITH SCHIZOPHRENIA SPE... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000212-22 | Sponsor Protocol Number: GWAP1241 | Start Date*: 2013-12-13 | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: A double-blind, randomised, placebo-controlled, parallel group study of GWP42003 as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder | |||||||||||||
Medical condition: Schizophrenia or related psychotic disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016715-38 | Sponsor Protocol Number: TEAprotocolversion3-12102009FINAL | Start Date*: 2010-02-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Copenhagen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: The TEA Trial- Tolerance and Effect of Antipsychotics in children and adolescents with psychosis An investigator-initiated, phase IV, randomised double-blind multi-centre trial of the benefits and... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: non-organic and non-drug-induced psychosis, meeting the criteria for ICD-10 diagnoses: F20, F22-F29 and F30.2, F31.2, F31.5, F32.3 and F33.3. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000565-23 | Sponsor Protocol Number: 2016-867 | Start Date*: 2017-03-03 | ||||||||||||||||||||||||||
Sponsor Name: | ||||||||||||||||||||||||||||
Full Title: TAILOR - a randomized clinical trial: Tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or schizophreniform psychosis in ... | ||||||||||||||||||||||||||||
Medical condition: Patients with newly diagnosed schizophrenia or schizophreniform psychosis in remission of psychotic symptoms | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005019-16 | Sponsor Protocol Number: ROCKSAN | Start Date*: 2009-03-19 |
Sponsor Name:AMC- academisch psychiatrisch centrum | ||
Full Title: Randomized Olanzapine Clozapine Key study on Schizophrenia and Addiction in the Netherlands (ROCKSAN) | ||
Medical condition: A multi-centre prospective, randomized, double blind designed study examining the effectiveness and costs of clozapine compared to olanzapine in patients with schizophrenia or related psychotic dis... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017024-82 | Sponsor Protocol Number: HSJD-EPEP09 | Start Date*: 2012-01-02 | |||||||||||
Sponsor Name:FUNDACIÓN SANT JOAN DE DEU | |||||||||||||
Full Title: Clinical and neuropsychological factors associated with second generation antipsychotic response in patients diagnosed with first episode of early onset schizophrenia spectrum disorders | |||||||||||||
Medical condition: First episode of early onset schizophrenia spectrum disorders | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005734-20 | Sponsor Protocol Number: R076477-SCA-3002 | Start Date*: 2008-04-24 | |||||||||||
Sponsor Name:Janssen L.P. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Flexible Dose Paliperidone ER in the Treatment of Subjects with Schizoaffective Disorder | |||||||||||||
Medical condition: Schizoaffective disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000163-32 | Sponsor Protocol Number: NorPEPS | Start Date*: 2017-06-29 |
Sponsor Name:Helse-Bergen HF | ||
Full Title: The Norwegian Prednisolone in Early Psychosis Study - NorPEPS The role of immune-modulating strategies in the treatment of psychosis | ||
Medical condition: Schizophrenia, schizophreniphorm disorder, schizoaffective disorder, psychosis NOS. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005399-16 | Sponsor Protocol Number: ROAC2014 | Start Date*: 2014-08-05 | |||||||||||
Sponsor Name:Dr. Benedicto Crespo. Servicio Psiquiatría. Hospital Universitario Marqués de Valdecilla/IDIVAL | |||||||||||||
Full Title: Randomized, flexible-dose, open-label comparison to investigate the effectivenes of second generation antipsychotics in first episode psychosis patients. | |||||||||||||
Medical condition: FIRST EPISODE DRUG-NAÏVE OF PSYCHOSIS (SCHIZOPHRENIA SPECTRUM DISORDERS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
